Vericel Buy Rating Reiterated as New Burlington Facility Underpins Long-Term Growth; $58 Price Target Maintained

Canaccord Genuity analyst Caitlin Roberts has maintained their bullish stance on VCEL stock, giving a Buy rating on June 10.

TipRanks' Prime Week Sale - 70% Off

• Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
• Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Caitlin Roberts has given his Buy rating due to a combination of factors that highlight Vericel’s growing operational strength and long-term growth visibility. The new Burlington, MA manufacturing facility offers substantially greater capacity than the legacy Cambridge site and is built to international regulatory standards, supporting both current MACI production and future international launches while reducing operational risk through redundant clean rooms and modern design.

Roberts also points to the company’s pipeline and geographic expansion as key drivers, including MACI Arthro, anticipated ex-U.S. rollouts starting with the U.K. in 2027, and an ankle indication in the next decade, all underpinned by the new site’s capacity. With the bulk of facility investment already completed, Vericel is positioned to generate meaningful cash that can be deployed into internal growth programs, acquisitions, or share repurchases, supporting a high-growth, profitable profile that justifies maintaining the $58 price target and Buy recommendation.

In another report released on June 10, TD Cowen also reiterated a Buy rating on the stock with a $55.00 price target.